Premium
Treatment of hepatitis C with interferon and ribavirin
Author(s) -
Pianko Stephen,
McHutchison John G
Publication year - 2000
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2000.02082.x
Subject(s) - ribavirin , medicine , hepatitis c , interferon , hepatitis c virus , combination therapy , alpha interferon , immunology , viral load , gastroenterology , virus
Hepatitis C is a worldwide problem that frequently results in end‐stage liver disease and its complications. Treatment for hepatitis C virus (HCV) has been rather ineffective but several recent studies have clarified the role of interferon and ribavirin therapy. In line with therapeutic progress in HIV infection, hepatitis C is now entering the era of multidrug antiviral therapy. Ribavirin is an orally active synthetic guanosine analogue with theoretical antiviral and immunomodulatory actions. In this review we have evaluated the role of interferon and ribavirin in treatment‐naive patients, relapsers and non‐responders. In naive patients the combination results in improved end‐of‐treatment and sustained response rates, with an overall 41% sustained virological response rate in patients treated for 48 weeks. Therapeutic benefit also extends to the traditionally difficult to treat patients (genotype 1, high viral load and advanced fibrosis). The addition of ribavirin to interferon has also resulted in an increased toxicity profile, which has made therapy more difficult for both the patient and managing physician. However, the significant improvement in response rates for all patients makes combination therapy the most appropriate choice as the first‐line therapy for suitable patients with chronic viral hepatitis C. Appropriate management with interferon and ribavirin includes assessing the patient’s HCV genotype to determine the optimal duration of therapy, assessing therapeutic efficacy by measuring HCV‐RNA at 24 weeks and monitoring for the additional ribavirin side‐effects.